Side population rather than CD133+ cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Zhou, Jianjun ^a,b   Wang, Honghe ^a   Cannon, Virginetta ^a   Wolcott, Karen M ^b   Song, Hongbin ^c   Yates, Clayton ^a  

^a TUSKEGEE UNIVERSITY   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Cancer Stem Cells; CD133; Prostate cancer; Side population (SP)

Indexed keywords

ALPHA6 INTEGRIN; CD133 ANTIGEN; HERMES ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL SELECTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROSTATE CANCER; SIDE POPULATION CELL; TUMOR XENOGRAFT; ANIMAL; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL AGGREGATION; CELL LINE; CELL SEPARATION; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; CELL AGGREGATION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SEPARATION; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PEPTIDES; PROSTATIC NEOPLASMS; SIDE-POPULATION CELLS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 80052859099     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-112     Document Type: Article

References (58)

1. Tsujimura A, Koikawa Y, Salm S, Takao T, Coetzee S, Moscatelli D, Shapiro E, Lepor H, Sun TT, Wilson EL. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 2002, 157:1257-1265. 10.1083/jcb.200202067, 2173539, 12082083.
2. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005, 65:6207-6219. 10.1158/0008-5472.CAN-05-0592, 16024622.
3. Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D, Wilson EL. TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol 2005, 170:81-90. 10.1083/jcb.200412015, 2171389, 15983059.
4. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461:495-500. 10.1038/nature08361, 2800362, 19741607.
5. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
6. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
8. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401. 10.1038/nature03128, 15549107.
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115. 10.1038/nature05384, 17122771.
10. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110. 10.1038/nature05372, 17122772.
11. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell 2007, 1:313-323. 10.1016/j.stem.2007.06.002, 18371365.
12. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166. 10.1016/j.ccr.2008.01.013, 18242515.
13. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000, 275:5512-5520. 10.1074/jbc.275.8.5512, 10681530.
14. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648. 10.1038/367645a0, 7509044.
15. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science 2007, 316:600-604. 10.1126/science.1139851, 17463288.
16. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657-667. 10.1056/NEJMoa040258, 15306667.
17. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951. 10.1158/0008-5472.CAN-05-2018, 16322242.
18. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008, 68:9703-9711. 10.1158/0008-5472.CAN-08-3084, 3072758, 19047148.
19. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-1034. 10.1038/nm0901-1028, 11533706.
20. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004, 101:14228-14233. 10.1073/pnas.0400067101, 521140, 15381773.
21. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
22. Mimeault M, Batra SK. Characterization of nonmalignant and malignant prostatic stem/progenitor cells by Hoechst side population method. Methods Mol Biol 2009, 568:139-149. 10.1007/978-1-59745-280-9_8, 19582424.
23. Lin KK, Goodell MA. Purification of hematopoietic stem cells using the side population. Methods Enzymol 2006, 420:255-264.
24. Majka SM, Jackson KA, Kienstra KA, Majesky MW, Goodell MA, Hirschi KK. Distinct progenitor populations in skeletal muscle are bone marrow derived and exhibit different cell fates during vascular regeneration. J Clin Invest 2003, 111:71-79. 151835, 12511590.
25. Miki J, Rhim JS. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis 2008, 11:32-39. 10.1038/sj.pcan.4501018, 17984999.
26. Miki J, Rhim JS. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis 2007,
27. Smith LG, Weissman IL, Heimfeld S. Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc Natl Acad Sci USA 1991, 88:2788-2792. 10.1073/pnas.88.7.2788, 51324, 1672767.
28. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598. 10.1038/nature07567, 2597380, 19052619.
29. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007, 67:3153-3161. 10.1158/0008-5472.CAN-06-4429, 17409422.
30. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004, 117:3539-3545. 10.1242/jcs.01222, 15226377.
31. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, 183:1797-1806. 10.1084/jem.183.4.1797, 2192511, 8666936.
32. Goodell MA, McKinney-Freeman S, Camargo FD. Isolation and characterization of side population cells. Methods Mol Biol 2005, 290:343-352.
33. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004, 101:781-786. 10.1073/pnas.0307618100, 321758, 14711994.
34. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res 2006, 66:1883-1890. discussion 1895-1886, 10.1158/0008-5472.CAN-05-3153, 16488983.
35. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823. 10.1038/nrd2137, 19794444.
36. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751. 10.1038/onc.2010.215, 20531305.
37. Vlashi E, Pajonk F. Targeted cancer stem cell therapies start with proper identification of the target. Mol Cancer Res 2010, 8:291. author reply 291, 2824786, 20145040.
38. Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL. Genomic profiling of tumor initiating prostatospheres. BMC Genomics 2010, 11:324. 10.1186/1471-2164-11-324, 2900264, 20500816.
39. Goodyear SM, Amatangelo MD, Stearns ME. Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense. Prostate 2009, 69:689-698. 10.1002/pros.20918, 2720608, 19143028.
40. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 70:875-882.
41. Sharifi N, Hurt EM, Farrar WL. Androgen receptor expression in prostate cancer stem cells: is there a conundrum?. Cancer Chemother Pharmacol 2008, 62:921-923. 10.1007/s00280-007-0659-5, 18075739.
42. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118:2111-2120. 2391278, 18497886.
43. Lobo NA, Shimono Y, Qian D, Clarke MF. The Biology of Cancer Stem Cells. Annu Rev Cell Dev Biol 2007, 23:675-699. 10.1146/annurev.cellbio.22.010305.104154, 17645413.
44. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98:1166-1173. 10.1182/blood.V98.4.1166, 11493466.
45. Setoguchi T, Taga T, Kondo T. Cancer stem cells persist in many cancer cell lines. Cell Cycle 2004, 3:414-415. 10.4161/cc.3.4.799, 15004528.
46. Dell'albani P. Stem Cell Markers in Gliomas. Neurochem Res 2008, 33:2407-2415. 10.1007/s11064-008-9723-8, 18493853.
47. Loebinger MR, Giangreco A, Groot KR, Prichard L, Allen K, Simpson C, Bazley L, Navani N, Tibrewal S, Davies D, Janes SM. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br J Cancer 2008, 98:380-387. 10.1038/sj.bjc.6604185, 2361447, 18219291.
48. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008, 268:1-9. 10.1016/j.canlet.2008.03.048, 18487012.
49. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349. 10.1038/nature06489, 18202660.
50. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598. 10.1038/nature07567, 2597380, 19052619.
51. Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. Int J Oncol 2004, 25:1057-1064.
52. Kim KH, Dobi A, Shaheduzzaman S, Gao CL, Masuda K, Li H, Drukier A, Gu Y, Srikantan V, Rhim JS, Srivastava S. Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase. Prostate Cancer Prostatic Dis 2007, 10:30-38. 10.1038/sj.pcan.4500915, 17075604.
53. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, Jin J, Liu D, Rhim JS, Rha SY, et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS ONE 2008, 3:e2990. 10.1371/journal.pone.0002990, 2500176, 18714356.
54. Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B, Rhim JS. A novel human cell culture model for the study of familial prostate cancer. Cancer Res 2001, 61:5969-5973.
55. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17:1253-1270. 10.1101/gad.1061803, 196056, 12756227.
56. Telford WG, Bradford J, Godfrey W, Robey RW, Bates SE. Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells 2007, 25:1029-1036. 10.1634/stemcells.2006-0567, 17185610.
57. Storms RW, Goodell MA, Fisher A, Mulligan RC, Smith C. Hoechst dye efflux reveals a novel CD7(+)CD34(-) lymphoid progenitor in human umbilical cord blood. Blood 2000, 96:2125-2133.
58. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008, 98:756-765. 10.1038/sj.bjc.6604242, 2259168, 18268494.